Effect of the HMG-CoA reductase inhibitor rosuvastatin on early chronic kidney injury in obese zucker rats fed with an atherogenic diet.

Full Abstract

The obese Zucker rat (OZR) spontaneously develops hyperlipidemia, insulin resistance, and microalbuminuria. In this study, the initial metabolic, functional, and glomerular pathology in young OZR fed with an atherogenic diet resembles the characteristics of metabolic syndrome. Hyperlipidemia and other metabolic derangement cause early glomerular damage in OZR by 10 weeks of age, before overt diabetes is developed. Consequently, the effects of potential interventions should also be evaluated at the young age. In OZR fed with an atherogenic high-fat diet, low (5 mg/kg) and high (20 mg/kg) dosages of rosuvastatin started at 5 weeks and maintained for 10 weeks induced a significant improvement in metabolic abnormalities, blood pressure, and renal function, including microalbuminuria. The low dose of rosuvastatin significantly decreased mesangial expansion, and the high dose exerted a marked protective effect on the development of both glomerular hypertrophy and mesangial expansion. The statin also attenuated the inflammatory expression in the kidney cortex.

Author information

Author/s: Reisin, Efrain (E); Ebenezer, Philip J (PJ); Liao, Jie (J); Lee, Benjamin S (BS); Larroque, Michelle (M); Hu, Xuejiao (X); Aguilar, Erwin A (EA); Morse, Stephen A (SA); Francis, Joseph (J);

Affiliation: Section of Nephrology and Hypertension, Department of Internal Medicine, Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112, USA. ereisi(-atsign-)lsuhsc.edu

Journal and publication information

Publication Type: Journal Article

Journal: The American journal of the medical sciences (Am J Med Sci), published in United States. (Language: eng)

Reference: 2009-Oct; vol 338 (issue 4) : pp 301-9

Dates: Created 2009/10/14; Completed 2009/10/26;

PMID: 19826320, status: MEDLINE (last retrieval date: 10/26/2009, IMS Date: )

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Gene Expression Profiling
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Insulin - blood
Kidney Failure, Chronic - metabolism; physiopathology; prevention & control
Lipids - blood; classification
Pyrimidines - therapeutic use
Rats
Rats, Zucker
Reverse Transcriptase Polymerase Chain Reaction
Sulfonamides - therapeutic use

Associated Chemicals: DNA Primers (0) ; Dietary Fats (0) ; Fluorobenzenes (0) ; Hydroxymethylglutaryl-CoA Reductase Inhibitors (0) ; Lipids (0) ; Pyrimidines (0) ; Sulfonamides (0) ; Insulin (11061-68-0) ; rosuvastatin (287714-41-4) ; C-Reactive Protein (9007-41-4)

These are the highest related articles currently in the database: